Dragonfly Therapeutics Inc. and Bristol Myers Squibb have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 investigational immunotherapy program, including its extended half-life cytokine DF6002.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
